Tekla Capital Management LLC is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
| ATHERSYS INC /OH | January 22, 2010 | 200,000 | 1.0% |
| VNUS MEDICAL TECHNOLOGIES INC | February 14, 2008 | 280,030 | 1.8% |
| ZIX CORP | February 14, 2008 | 885,000 | 1.4% |
| AVALON PHARMACEUTICALS INC | February 09, 2007 | 405,721 | 4.0% |
| MATRITECH INC/DE/ | February 09, 2007 | 8,093,105 | 12.2% |
| SENOMYX INC | February 14, 2006 | 334,250 | 1.3% |